ABSTRACT
Osteoporosis is still an underdiagnosed and insufficiently therapied widespread disease in Germany. Of the estimated 7 million osteoporosis patients only 1.5 million receive a guideline conform diagnosis and even less receive appropriate treatment. Some 90 % of patients are provided with analgesics but only 10 % receive an effective therapy, although efficacious, well-tested and affordable medications are available. In addition, approximately one half of the patients terminate treatment after only 1 year although according to the results of recent studies the duration of therapy should be at least 3-5 years. In view of the increasing average life expectancy, a consistent management for prevention of fractures associated with osteoporosis is always most important for society, even if only for reasons of costs. Achievement of this target depends on four circumstances: clarification of the origin of osteoporosis and fractures (bone consciousness), prophylaxis of bone loss and fractures (primary prevention), consistent guideline conform diagnostics and therapy (secondary and tertiary prevention) and cooperation of all disciplines in medicine (bone is everybody's business). This article describes the current state of diagnostics (bone density measurement with dual X-ray absorptiometry, FRAX®), prophylaxis of fractures (screening program) and therapy (use of economic and effective medications with low side effects). Novel medications are already undergoing clinical testing and a "healing" of bone reduction with restoration of the normal bone structure is to be expected.
Subject(s)
Absorptiometry, Photon/methods , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Mass Screening/methods , Osteoporotic Fractures/diagnosis , Osteoporotic Fractures/therapy , HumansSubject(s)
Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Fractures, Bone/chemically induced , Fractures, Bone/prevention & control , Proton Pump Inhibitors/administration & dosage , Proton Pump Inhibitors/adverse effects , Administration, Oral , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Drug Interactions , Humans , Risk FactorsSubject(s)
Bone Density Conservation Agents/adverse effects , Bone Diseases, Metabolic/drug therapy , Diphosphonates/adverse effects , Jaw Diseases/chemically induced , Osteomyelitis/chemically induced , Osteonecrosis/chemically induced , Osteoporosis/drug therapy , Administration, Oral , Aged , Alendronate/adverse effects , Alendronate/therapeutic use , Bone Density/drug effects , Bone Density Conservation Agents/therapeutic use , Diphosphonates/therapeutic use , Drug Approval , Female , Humans , Imidazoles/adverse effects , Imidazoles/therapeutic use , Infusions, Intravenous , Opportunistic Infections/chemically induced , Pamidronate , Practice Guidelines as Topic , Risk Factors , Zoledronic AcidABSTRACT
Due to increasing knowledge on pathogenetic factors causing osteoporosis and increasingly more detailed investigations, the diagnosis of secondary osteoporosis is being made increasingly more often. A rational search for the underlying disease or the bone-damaging medication is indicated particularly in adolescents, premenopausal women, men and postmenopausal women with rapidly decreasing bone tissue. The early detection of the causative disease in the preclinical stage of osteoporosis and the current therapeutic options allow not only normalization of the bone structure and the risk of fracture but also targeted therapy of the cause of the osteoporosis. The focal point in the diagnostics of secondary osteoporosis is still dual energy X-ray absorptiometry (DXA) measurement together with the manifold imaging procedures in radiology and additional clinical, laboratory chemical and bioptic findings.
Subject(s)
Absorptiometry, Photon/methods , Diagnostic Imaging/methods , Osteoporosis/diagnosis , Osteoporosis/epidemiology , Osteotomy/methods , Adolescent , Adult , Bone Density Conservation Agents/therapeutic use , Causality , Female , Humans , Incidence , Male , Middle Aged , Osteoporosis/therapyABSTRACT
A number of drugs can have "side effects" on bone metabolism and formation, causing bone atrophy, impaired mineralisation, as well as osteonecrosis. In both clinical and general practitioner settings, these forms of bone damage have been hitherto considered as adverse drug side effects and have received insufficient attention; moreover, they have not been the subject of patient information. Preventive measures are not instigated prior to initiation of medication and even after onset of bone damage, therapeutic strategies are poorly implemented. Even fracture healing with its complex, staged course can be both positively and negatively influenced by a number of drugs and these effects require monitoring. Recommendations regarding practical screening and therapy of drug-induced osteopathies are presented.
Subject(s)
Bone Diseases/chemically induced , Prescription Drugs/adverse effects , Anti-HIV Agents/adverse effects , Anti-HIV Agents/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antiretroviral Therapy, Highly Active/adverse effects , Bone Diseases/diagnosis , Bone Diseases/prevention & control , Bone Diseases/therapy , Fracture Healing/drug effects , Fractures, Spontaneous/chemically induced , Fractures, Spontaneous/diagnosis , Fractures, Spontaneous/prevention & control , Fractures, Spontaneous/therapy , Humans , Osteomalacia/chemically induced , Osteomalacia/diagnosis , Osteomalacia/prevention & control , Osteomalacia/therapy , Osteonecrosis/chemically induced , Osteonecrosis/diagnosis , Osteonecrosis/prevention & control , Osteonecrosis/therapy , Osteoporosis/chemically induced , Osteoporosis/diagnosis , Osteoporosis/prevention & control , Osteoporosis/therapyABSTRACT
A number of drugs can have "side effects" on bone metabolism and formation, causing bone atrophy, impaired mineralisation, as well as osteonecrosis. In both clinical and general practitioner settings, these forms of bone damage have been hitherto considered as adverse drug side effects and have received insufficient attention; moreover, they have not been the subject of patient information. Preventive measures are not instigated prior to initiation of medication and even after onset of bone damage, therapeutic strategies are poorly implemented. Even fracture healing with its complex, staged course can be both positively and negatively influenced by a number of drugs and these effects require monitoring. Recommendations regarding practical screening and therapy of drug-induced osteopathies are presented.
Subject(s)
Bone Diseases, Metabolic/chemically induced , Drug-Related Side Effects and Adverse Reactions/chemically induced , Drug-Related Side Effects and Adverse Reactions/prevention & control , Bone Diseases, Metabolic/diagnosis , Drug-Related Side Effects and Adverse Reactions/diagnosis , HumansABSTRACT
Two patients aged 24 and 64 years presented at our hospital with similar symptoms including bone pain and muscle weakness. Basic laboratory tests and urinary diagnostics, bone densitometry and bone histology revealed severe osteomalacia with renal phosphate wasting. After the exclusion of other causes an extensive tumor search was performed due to suspected tumor-induced osteomalacia. In one patient a mesenchymal tumor was found in the thigh and completely resected. After surgery the patient showed a rapid recovery from osteomalacia. Because the search was unsuccessful in the other patient phosphorus supplementation in combination with calcitriol was started. Despite continuing renal phosphate wasting a significant increase in bone mineral density was observed.
Subject(s)
Arthralgia/diagnosis , Arthralgia/etiology , Hypophosphatemia/diagnosis , Hypophosphatemia/etiology , Osteomalacia/diagnosis , Osteomalacia/etiology , Soft Tissue Neoplasms/complications , Humans , Middle Aged , Soft Tissue Neoplasms/diagnosis , Young AdultSubject(s)
Absorptiometry, Photon/instrumentation , Fractures, Spontaneous/prevention & control , Osteoporosis/prevention & control , Accidental Falls/prevention & control , Bone Density Conservation Agents/therapeutic use , Combined Modality Therapy , Fractures, Spontaneous/diagnosis , Fractures, Spontaneous/rehabilitation , Humans , Osteoporosis/diagnosis , Osteoporosis/rehabilitation , Practice Guidelines as Topic , Tomography, X-Ray ComputedSubject(s)
Bone and Bones/metabolism , Calcium/metabolism , Diphosphonates/pharmacokinetics , Osteoporosis/drug therapy , Bone Neoplasms/complications , Bone Neoplasms/pathology , Calcium/therapeutic use , Diphosphonates/therapeutic use , Half-Life , Humans , Hydrogen-Ion Concentration , Jaw/chemistry , Jaw/metabolism , Jaw/pathology , Necrosis , Osteoclasts/drug effects , Osteoporosis/etiology , Osteoporosis/prevention & control , Vitamin D/pharmacology , Vitamin D/therapeutic useABSTRACT
Osteoporosis is one of the 10 most important and widespread global diseases. In Germany alone the cost of osteoporosis runs into many billions of Euros. However, it should be noted that in the past 15 years great progress has been made both in diagnosis and in the development of new medications, and this has changed the general perception of and attitude to osteoporosis. It is now taken very seriously and recognised as a national and global disorder which is both preventable and treatable. In spite of this progress, in Europe and especially in Germany, osteoporosis remains an underdiagnosed and undertreated disease. In Germany, only about 10%-15% of patients with manifest osteoporosis are properly treated. However, in addition to national guidelines, there is now a new edition of the "European Position Paper for the Diagnosis and Management of Osteoporosis". This provides physicians treating osteoporosis patients with additional information and therefore more confidence.
Subject(s)
Orthopedics/standards , Orthopedics/trends , Osteoporosis/diagnosis , Osteoporosis/therapy , Practice Guidelines as Topic , Europe , HumansSubject(s)
Osteoporosis, Postmenopausal/diagnosis , Osteoporosis, Postmenopausal/therapy , Absorptiometry, Photon , Aged , Aged, 80 and over , Bone Density , Bone Density Conservation Agents/economics , Bone Density Conservation Agents/therapeutic use , Cost-Benefit Analysis , Female , Fractures, Bone/economics , Fractures, Bone/etiology , Fractures, Bone/prevention & control , Humans , Male , Middle Aged , Osteoporosis, Postmenopausal/complications , Quality-Adjusted Life Years , Risk FactorsSubject(s)
Bone Density Conservation Agents/pharmacokinetics , Bone and Bones/metabolism , Diphosphonates/pharmacokinetics , Osteoporosis/drug therapy , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Half-Life , Humans , Hydrogen-Ion Concentration , Tissue DistributionSubject(s)
Bone Density Conservation Agents/therapeutic use , Bone Neoplasms/secondary , Bronchial Neoplasms/pathology , Diphosphonates/therapeutic use , Osteoporosis/drug therapy , Administration, Oral , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/complications , Clodronic Acid/administration & dosage , Clodronic Acid/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Female , Humans , Ibandronic Acid , Imidazoles/administration & dosage , Imidazoles/therapeutic use , Injections, Intravenous , Osteoporosis/etiology , Osteoporosis/prevention & control , Zoledronic AcidABSTRACT
Osteoporosis is one of the ten most important and widespread global diseases. In Germany alone the costs of osteoporosis run into billions of Euros. However, during the past 15 years great progress has been made both in diagnosis and in the development of new medications. Osteoporosis is now taken very seriously and recognized as a national and global disorder which is now both preventable and treatable. Nevertheless, at a practical level, both in Europe and especially in Germany, osteoporosis remains an underdiagnosed and undertreated disease. In Germany, only about 10-15% of patients with manifest osteoporosis are properly treated. The consequences of such inadequate care are high additional costs-not to mention the unnecessary suffering of the patients involved. However, in support of national guidelines, a new edition of the "European Position Paper for the Diagnosis and Management of Osteoporosis" provides the doctors who treat patients with osteoporosis with additional information and therefore more confidence. In this paper several aspects are emphasized: improvements in diagnostic evaluation, assessment of the efficacy of fracture-oriented medications, and cost-effectiveness of the treatment of patients with osteoporosis.
Subject(s)
Fractures, Spontaneous/economics , Fractures, Spontaneous/therapy , Health Care Costs/statistics & numerical data , Osteoporosis/economics , Osteoporosis/therapy , Practice Guidelines as Topic , Cost-Benefit Analysis , Europe/epidemiology , Fractures, Spontaneous/epidemiology , Osteoporosis/epidemiologyABSTRACT
Over the past three decades, the members of the substance group called bisphosphonates (BP) have been employed with growing success to manage osteopathies caused by increased osteoclastic activity. The following developments in BP are responsible: Modern BP are now already 20,000 times more potent than the first preparation approved for use. Their biochemical and cellular mechanisms of action have meanwhile been elucidated. They have no effect on hormones so that they are open for all patients. They are well tolerated and can be administered orally or intravenously. They have admirably been thoroughly studied in multinational trials. They are the "gold standard" in the treatment of osteoporosis, a widespread disease. Rare but serious side effects such as osteonecrosis of the jaw or acute renal insufficiency can be avoided to a large extent. BP also have tumoricidal properties and are used to suppress tumor growth in bones. Their anti-inflammatory activity is also successfully used in the treatment of bone marrow edema and bone pain.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Diseases/drug therapy , Bone Neoplasms/secondary , Diphosphonates/therapeutic use , Fracture Healing/drug effects , Fractures, Spontaneous/drug therapy , Osteoporosis/drug therapy , Administration, Oral , Bone Density Conservation Agents/adverse effects , Bone Diseases/pathology , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Diphosphonates/adverse effects , Diphosphonates/chemistry , Fractures, Spontaneous/pathology , Humans , Infusions, Intravenous , Jaw Diseases/chemically induced , Jaw Diseases/pathology , Osteoclasts/drug effects , Osteoclasts/pathology , Osteonecrosis/chemically induced , Osteonecrosis/pathology , Osteoporosis/pathology , Structure-Activity RelationshipABSTRACT
Published reports of studies on the long-term effects of anti-epileptic drugs (AED) on bone--its density, thickness, vitamin D metabolism and risk of fracture--have shown considerable methodological inadequacies (34). Despite these problems it has been clearly shown that patients with epilepsy who are on anti-epileptic drugs have a greater than normal risk of bone loss, abnormal mineralization and fractures. A patient on long-term treatment with AED has a two- to three-fold risk of sustaining a fracture. On average 50% of patients (ranging from 4-70% in different studies [18]) have an osteopathy (34). Type, dosage and duration of AED treatment determine the exact picture of the osteopathy--regardless of whether or not they are enzyme-inducing. Among the enzyme-inducing drugs, especially phenytoin, primidone, phenobarbital and carbamezapine have been investigated for their influence on vitamin D metabolism. Bone loss has also been noted even without evidence of vitamin D deficiency. Mixed forms of osteoporosis and osteomalacia occur particularly often and must be taken into account in any differentiated form of treatment. But the question remains unanswered whether current AEDs, such as lamotrigine, gabapentin or levetiracetam will cause little or no osteopathy. Comparable to the situation during long-term systemic administration of glucocorticoids, initial diagnosis, including the inexpensive dual-energy X-ray absorptiometry (DXA) and the serum concentration of 25-hydroxyvitamin D, must be obtained to determine whether initially there are any bone changes. In addition to a differentiated and clearly defined treatment of osteopathy in a patient with epilepsy, the aim must be to minimize the tendency towards seizures and their severity. The annual cost of adequate vitamin D substitution is about EUR 50, while biphosphonate treatment costs about EUR 500; the costs of vertebral or forearm fractures are about EUR 1000 and those of hip fracture about EUR 15,000. These figures exclude the costs of rehabilitation, nursing care and loss of earnings. Looked at in this way, the problem of AED-induced osteopathy has been underestimated. Yet it is actually preventable and--if already present--can be efficaciously and inexpensively treated when the new guidelines of the (German) Joint Organization of Osteology are followed. The prerequisite of rational treatment is a diagnostically clear distinction of osteoporosis and osteomalacia, but mixed forms are common. ("osteoporomalacia"). Further investigations of more recently developed AEDs (e.g. gabapentin, lamotrigine or levetiracetam) regarding their damaging action on bone during their long-term administration is essential. Systematic control of the state of bones in all patients on long-term treatment with AEDs is nowadays recommended without qualification, even though some study data are unsatisfactory or even lacking.
Subject(s)
Anticonvulsants/adverse effects , Osteomalacia/chemically induced , Osteoporosis/chemically induced , Vitamin D , Anticonvulsants/therapeutic use , Bone Density/drug effects , Bone Density Conservation Agents/blood , Bone Density Conservation Agents/economics , Bone Density Conservation Agents/metabolism , Bone Density Conservation Agents/therapeutic use , Cost-Benefit Analysis , Diagnosis, Differential , Epilepsy/drug therapy , Fractures, Bone/economics , Fractures, Bone/prevention & control , Humans , Osteomalacia/diagnosis , Osteomalacia/economics , Osteomalacia/prevention & control , Osteoporosis/diagnosis , Osteoporosis/economics , Osteoporosis/prevention & control , Risk Factors , Vitamin D/blood , Vitamin D/economics , Vitamin D/metabolism , Vitamin D/therapeutic useSubject(s)
Evidence-Based Medicine , Osteoporosis/therapy , Absorptiometry, Photon , Adult , Age Factors , Aged , Aged, 80 and over , Alendronate/administration & dosage , Alendronate/therapeutic use , Bone Density , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Cost-Benefit Analysis , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Female , Humans , Male , Middle Aged , Osteoporosis/diagnosis , Osteoporosis/diagnostic imaging , Osteoporosis/drug therapy , Osteoporosis/economics , Osteoporosis/prevention & control , Osteoporosis, Postmenopausal/diagnosis , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/economics , Physical Examination , Practice Guidelines as Topic , Primary Prevention , Risk FactorsABSTRACT
Since the World Health Organisation's announcement of the "Bone and Joint Decade 2000-2010" diseases of the musculoskeletal system attract more and more attention throughout patients and professional health care providers. In an aging society especially osteoporosis represents a major public health concern. Fragility fractures are the most limiting condition in osteoporosis with the highest impact on both, life quality and health care systems worldwide. Orthopaedic surgeons play a key role in implementing primary diagnostics and therapy in patients with fragility fractures. Objective of this effort is the reduction of the common subsequent fractures in patients with osteoporosis. According to national and international guidelines implementation of contemporary clinical pathways to diagnose and treat patients with fractures due to diminished bone mineral density is fast, simple and proven to be effective.